Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J Cancer Drug Zytiga Now Backed For Publicly Funded Use In UK

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2012 | 11:11am CET

The U.K.'s health-care cost-effectiveness regulator Wednesday reversed an earlier decision and approved the publicly funded use of Johnson & Johnson's (JNJ) prostate-cancer pill Zytiga, after the U.S. company cut its price further.

Also known as abiraterone, Zytiga removes the prostate cancer tumor's supply of testosterone, preventing it from growing further and potentially extending a patient's life by more than three months. The medicine was rejected for use in the U.K. in February on grounds its terms of use wouldn't offer value for money.

Andrew Dillon, chief executive of the U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said the manufacturer subsequently submitted fresh information, including a revised patient access scheme containing a deeper price discount to the National Health Service and more information about which patients would most benefit from its use and how many patients could receive the drug.

"These factors enabled the committee to revise its preliminary recommendation and now recommend the drug for use on the NHS," Dillon said in a statement. "It is an effective treatment, potentially extending life by more than three months, and it also allows patients to be treated at home as it can be taken orally."

Abiraterone costs GBP2,930 for a 30-day supply of 120 tablets. NICE didn't specify the size of the price cut offered by Johnson & Johnson.

Zytiga was approved by U.S. and European drug regulators last year. It is set to generate peak-year sales of $910 million.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
01/18 JOHNSON & JOHNSON : J&J Convenes Eating Disorder Leadership Summit
01/18 JOHNSON & JOHNSON : Technical Reports on Drug Makers Stocks -- Pfizer, Merck, Ab..
01/14 JOHNSON & JOHNSON : Dancing with Abilene Stars raises $446,000
01/13 JOHNSON & JOHNSON : Ask The Doctors
01/13 JOHNSON & JOHNSON : Evidence not conclusive about talc Ask the Doctors
01/13 ROCHE : Johnson & Johnson and Alstrom Syndrome UK Address Hot Topic of Paediatri..
01/12 JOHNSON & JOHNSON : Study Findings from Johnson & Johnson Broaden Understanding ..
01/12 JOHNSON & JOHNSON : Missouri Court Denies J&J Request to Delay Talc-Related Canc..
01/12 JOHNSON & JOHNSON : Innovation's Global Pursuit of Cutting-Edge Science Yields 1..
01/11 CORRECTION : Drug Prices-Johnson & Johnson story
More news
Sector news : Pharmaceuticals - NEC
02:17aDJMALLINCKRODT : to Pay $100 Million to Settle Antitrust Allegations on Unlawful D..
01/18DJCSL : Expects Higher Profits On Strong Immunoglobulin Sales -- Update
01/18DJCSL : Expects Higher 1st Half Profits On Strong Immunoglobulin Sales
01/18DJMALLINCKRODT : to Pay $100 Million to Settle Antitrust Allegations on Unlawful D..
01/18DJELI LILLY AND : to Buy Migraine Drug Developer CoLucid Pharmaceuticals
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 Valeant Gives Up Gains
01/18 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q4 2016 Update
01/17 Even A $100M Series A Can't Save The Medtech Venture Climate
01/17 AnaptysBio Sets Terms For $60 Million IPO
01/17 Beating The Market In 2016
Financials ($)
Sales 2016 72 019 M
EBIT 2016 21 880 M
Net income 2016 16 368 M
Finance 2016 16 902 M
Yield 2016 2,74%
P/E ratio 2016 19,43
P/E ratio 2017 17,15
EV / Sales 2016 4,10x
EV / Sales 2017 3,84x
Capitalization 312 045 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 125 $
Spread / Average Target 9,1%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.44%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.39%194 551
NOVARTIS AG-3.71%185 185
MERCK & CO., INC.3.91%169 509
SANOFI-0.52%105 039
More Results